Orthocell Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Orthocell has a total shareholder equity of A$4.5M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$26.6M and A$22.1M respectively.

Anahtar bilgiler

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranı	n/a
Nakit	AU$20.61m
Eşitlik	AU$4.53m
Toplam yükümlülükler	AU$22.08m
Toplam varlıklar	AU$26.62m

Son finansal sağlık güncellemeleri

Recent updates

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Sep 09

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Oct 25

We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth

Nov 16

We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Jul 29

Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans

Mar 23

We're Not Worried About Orthocell's (ASX:OCC) Cash Burn

Dec 08

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

May 31

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Feb 15

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

Dec 24

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: OCC's short term assets (A$23.0M) exceed its short term liabilities (A$5.3M).

Uzun Vadeli Yükümlülükler: OCC's short term assets (A$23.0M) exceed its long term liabilities (A$16.8M).

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: OCC is debt free.

Borcun Azaltılması: OCC has not had any debt for past 5 years.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: OCC has sufficient cash runway for more than a year based on its current free cash flow.

Tahmini Nakit Akışı: OCC has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 21% each year.

Orthocell Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth

We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans

Orthocell Ordinary Shares to Be Deleted from Other OTC

We're Not Worried About Orthocell's (ASX:OCC) Cash Burn

Recent updates

Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 17 million.

Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 17 million.

CEO, MD & Executive Director exercised options to buy AU$190k worth of stock.

Orthocell Limited, Annual General Meeting, Nov 29, 2024

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Full year 2024 earnings released: AU$0.036 loss per share (vs AU$0.032 loss in FY 2023)

Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 3.500001 million.

New minor risk - Shareholder dilution

Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.

Orthocell Limited Announces Resignation of Matthew Callahan from the Board

Orthocell Limited Announces Changes to its Board

Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Orthocell Limited Announces Board Changes

Less than half of directors are independent

Orthocell Limited Announces Board Changes

Orthocell Limited, Annual General Meeting, Oct 31, 2023

Full year 2023 earnings released: AU$0.032 loss per share (vs AU$0.047 loss in FY 2022)

New minor risk - Financial data availability

Orthocell Limited Appoints John Van Der Wielen as Independent Non-Executive Chairman, Effective 1 June 2023

First half 2023 earnings released: AU$0.021 loss per share (vs AU$0.024 loss in 1H 2022)

We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth

Less than half of directors are independent

Orthocell Limited's Rotator Cuff Study Success with Cross-Over Patients

Orthocell Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.047 loss per share (vs AU$0.048 loss in FY 2021)

We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Orthocell Limited Announces the Completion of Its RemplirTM Nerve Reconstruction Study

Less than half of directors are independent

Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans

Orthocell Ordinary Shares to Be Deleted from Other OTC

We're Not Worried About Orthocell's (ASX:OCC) Cash Burn

CEO, MD & Executive Director recently sold AU$552k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2021 earnings released: AU$0.047 loss per share (vs AU$0.036 loss in FY 2020)

Orthocell Limited Announces CelGro Nerve Study Results

Orthocell Limited Announces First Interim Data Read Out of All Patients in the Celgro® Nerve Regeneration Trial At 12 Months Post Treatment

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

Orthocell Limited Announces New Collagen Rope Patent for CelGro Platform Technology

Celgro Study Results Open Up New US Market Access Strategy

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Orthocell Limited Announces Publication of Successful Case Study Focussing on the Combination of Celgro® Collagen Medical Device and Autologous Tenocyte Implantation for the Surgical Repair of Large Degenerate Tear of the Gluteal Medius Tendo

Orthocell Ltd Receives US Market Clearance

Orthocell Limited Receives First US CelGro Product Approval

New 90-day high: AU$0.49

Orthocell Limited Receives Australian Market Approval for its Celgro, a Collagen Medical Device

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

New 90-day high: AU$0.46

Orthocell Limited Announces Patient Enrolment for the Celgro® Nerve Regeneration Trial Is Now Complete

New 90-day low: AU$0.33

Orthocell Limited Announces CelGro Bone Regeneration in Dental & Orthopedic Applications

Full year earnings released - AU$0.036 loss per share

New 90-day high - AU$0.43

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin